SCHEMBL676341

SCHEMBL676341

O=c1c(-c2ccc(O)c(O)c2O)c(O)oc2ccccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.55
KDM5A P29375 1/20 0.49
MAOA P21397 7/20 0.47
CYP3A4 P08684 6/20 0.47
KDM4E B2RXH2 5/20 0.47
HSD17B10 Q99714 5/20 0.47
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
ALOX15 P16050 4/20 0.47
MAPT P10636 3/20 0.47
TP53 P04637 3/20 0.47
MAPK1 P28482 3/20 0.47
CYP2D6 P10635 2/20 0.47
CYP2C9 P11712 2/20 0.47
ALOX12 P18054 2/20 0.47
CYP2C19 P33261 2/20 0.47
RECQL P46063 2/20 0.47
ST6GAL1 P15907 1/20 0.47
CDK2 P24941 1/20 0.47
HPGD P15428 4/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1255489 0.88 CYP3A4 (0.57) PTGS2KDM5AMAOACYP3A4KDM4E
SCHEMBL1607109 0.83 MAOA (0.56) PTGS2KDM5AMAOACYP3A4KDM4E
SCHEMBL157971 0.81 KDM4E (0.64) PTGS2KDM5AMAOACYP3A4KDM4E
SCHEMBL571524 0.76 MAOA (0.59) MAOACYP3A4KDM4EHSD17B10MEN1
SCHEMBL2318320 0.76 CA1 (0.65) KDM5AMAOACYP3A4KDM4EHSD17B10
SCHEMBL1180659 0.75 KDM4E (0.62) PTGS2KDM5AMAOACYP3A4KDM4E
SCHEMBL1772778 0.73 HPGD (0.78) CYP3A4KDM4EHSD17B10MEN1KMT2A
SCHEMBL1445004 0.72 MAOA (0.69) PTGS2KDM5AMAOACYP3A4KDM4E
SCHEMBL29633014 0.72 MAOA (0.69) PTGS2KDM5AMAOACYP3A4KDM4E
SCHEMBL10655426 0.72 MAPK14 (0.59) PTGS2MAOACYP3A4KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190142940-A1 Method and system for effecting changes in pigmented tissue MOAZED KAMBIZ THOMAS (US) 2019-05-16 US claimed
US-20120207809-A1 Method and system for effecting changes in pigmented tissue MOAZED KAMBIZ THOMAS (US) 2012-08-16 US claimed
US-20120076848-A1 METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE MOAZED KAMBIZ THOMAS (US) 2012-03-29 US claimed
US-20110280909-A1 METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE MOAZED KAMBIZ THOMAS (US) 2011-11-17 US claimed
WO-2011011065-A1 METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE MOAZED KAMBIZ THOMAS (US) 2011-01-27 WO claimed
WO-2010087983-A1 METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE MOAZED KAMBIZ THOMAS (US) 2010-08-05 WO claimed
US-20240042396-A1 Polymeric Membrane SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2024-02-08 US disclosed
EP-4259316-A2 POLYMERIC MEMBRANE 3M Innovative Properties Company (US) 2023-10-18 EP disclosed
US-20230255989-A1 GLYCAN COMPOSITIONS AND USES THEREOF DSM NUTRITIONAL PRODUCTS LLC (US) 2023-08-17 US disclosed
WO-2022123428-A2 POLYMERIC MEMBRANE 3M INNOVATIVE PROPERTIES COMPANY (US) 2022-06-16 WO disclosed
CN-114128892-A Probiotic stabilization MJN 美国控股有限责任公司 2022-03-04 CN disclosed
US-11229660-B2 Glycan therapeutics and method of treating conditions associated with TMAO KALEIDO BIOSCIENCES, INC. (US) 2022-01-25 US disclosed
US-20210137956-A1 GLYCAN COMPOSITIONS AND USES THEREOF HERCULES CAPITAL, INC. 2021-05-13 US disclosed
US-20120076848-A1 METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE MOAZED KAMBIZ THOMAS (US) 2012-03-29 US disclosed
US-20110280909-A1 METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE MOAZED KAMBIZ THOMAS (US) 2011-11-17 US disclosed
US-20110186518-A1 POLYMER COMPOSITION WITH PHYTOCHEMICAL AND DIALYSIS MEMBRANE FORMED FROM THE POLYMER COMPOSITION THE UNIVERSITY OF AKRON (US) 2011-08-04 US disclosed
WO-2011011065-A1 METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE MOAZED KAMBIZ THOMAS (US) 2011-01-27 WO disclosed
WO-2010087983-A1 METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE MOAZED KAMBIZ THOMAS (US) 2010-08-05 WO disclosed
US-20080317880-A1 PLANT ISOFLAVONE AND ISOFLAVANONE O-METHYLTRANSFERASE GENES THE SAMUEL ROBERTS NOBLE FOUNDATION 2008-12-25 US disclosed
WO-2008022265-A2 PLANT ISOFLAVONE AND ISOFLAVANONE O-METHYLTRANSFERASE GENES THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. (US) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110186518-A1 POLYMER COMPOSITION WITH PHYTOCHEMICAL AND DIALYSIS MEMBRANE FORMED FROM THE POLYMER COMPOSITION MATR3, ATP6V1B1, CD68 PTGS2 2984/4885KDM5A 1531/4885MAOA 2005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.